Ethk Labs

Ethk Labs FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Ethk Labs (1931.HK) as of Nov 3, 2026 is -2,891.64 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 34.05 % — a change of -8,591.20% (lower).

FCF Conversion

-2,891.64 %

YoY

-8,591.20%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Ethk Labs is 2025 -2,891.64 % . FCF Conversion Rate (FCF/EBITDA) of Ethk Labs was 2024 34.05 % . It decreases by -8,591.20% lower compared to the previous year.

The Ethk Labs FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-14.00 CNY
Jan 1, 2019
112.65 CNY
Jan 1, 2020
91.27 CNY
Jan 1, 2021
78.99 CNY
Jan 1, 2022
102.57 CNY
Jan 1, 2023
105.77 CNY
Jan 1, 2024
34.05 CNY
Jan 1, 2025
-2,891.64 CNY
The Ethk Labs FCF Conversion history
YEARFCF ConversionYoY
-2,891.64 %-8,591.20%
34.05 %-67.80%
105.77 %+3.13%
102.57 %+29.84%
78.99 %-13.46%
91.27 %-18.98%
112.65 %-904.75%
-14.00 %-1,027.66%
1.51 %-101.85%
-81.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ethk Labs Stock analysis

What does Ethk Labs do? IVD Medical Holding Ltd. generates revenue through the sale and manufacture of medical equipment and consumables, primarily focusing on IVD analyzers, reagents, and related consumables. The company's distribution business handles the sales of these products, while its self-branded products business involves developing, producing, and selling its own IVD products. Additionally, the firm offers repair services for its self-branded IVD products, creating a recurring revenue stream from maintenance and support. The company targets healthcare providers and medical facilities that require diagnostic equipment and consumables. Its self-branded IVD products cater to the growing demand for in-house diagnostic solutions, while the distribution segment serves as a key channel for third-party products. Repair services further strengthen customer relationships by ensuring product longevity and reliability. IVD Medical Holding Ltd. operates with a dual revenue model: direct sales of self-branded IVD products and distribution of third-party analyzers and reagents. The company's focus on both manufacturing and distribution allows it to capture value across the diagnostic supply chain, from product development to end-user support. Ethk Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ethk Labs stock

FCF Conversion Rate (FCF/EBITDA) of Ethk Labs is -2,891.64 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Ethk Labs changed from 34.05 % to -2,891.64 %, representing a -8,591.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Ethk Labs since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Ethk Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ethk Labs

All Key Metrics — Ethk Labs